Advanced Biomed Inc. confirmed in its fiscal 2026 annual report, filed October 13, that it has completed its shift from biomedical operations to AI-powered financial verification. It divested its legacy subsidiaries and acquired Acellent Technologies (Hong Kong) to enter the fintech market.
The company reported fiscal-year net income of $6.68 million, reversing the prior year’s loss. A one-time $14 million gain from the disposal of its former businesses was the primary driver of that profit.
Its continuing AI operations recorded a loss of $6.26 million. They generated approximately $127,600 in their first-ever revenue.